Figure 6: ATO induced expression of SIRPα through the suppression of miR-17, miR-20a, and miR-106a.

(a) The level of SIRPα-regulating miRNAs, miR-17, miR-20a, miR-106a in HL-60 or NB4 cells treated with ATO at indicated time. The level of all miRNAs was normalized to that of U6. (b) The relative mRNA level of SIRPα in HL-60 or NB4 cells treated with ATO for indicated time. Total RNA was extracted from the cells and analyzed with RT-qPCR. The mRNA level of GAPDH was used as an internal control. (c) Western blotting of SIRPα protein level in the HL-60 or NB4 cells treated with ATO for indicated time. Before ATO treatment, the cells were transfected with pre-miR-17. The mock-transfected cells (PBS) or cells transfected with scrambles oligonucleotide were used as a control: representative Western blot (upper panel) and quantitative analysis (lower panel). (d) Flow cytometry analysis of apoptosis of pre-miR-17-transfected HL-60 or NB4 cells after the treatment of ATO for 48 h: representative flow cytometer data (left panel) and quantitative analysis of apoptosis (right panel). The percentage of annexin V-positive cells was calculated. Values were shown as the mean ± SEM (n = 3). *P < 0.05. **P < 0.01.